REFERENCES
- Consensus document of antiretroviral therapy in adults with human immunodeficiency virus infection (updated January 2010). AIDS Study Group/Spanish AIDS Plan [in Spanish]. Enferm lnfecc Microbiol Clin. 2010;28(6):362. e1-91. Epub May 31, 2010.
- Panel on Antiretroviral Guidelines for Adults and Adoles-cents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 1, 2009. http://www.aidsinfo.nih.gov/contentfiles/AdultandAdoles-centGL.pdf.
- Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008; 9(2):65— 71.
- Blanco JL, Biglia A, De Lazzari E, et al. Antiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutations. AIDS. 2006;20(14)1891–1892.
- Marcelin AG, Flandre P, Pavie J, et al. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother 2005;49(5):1739–1744.
- Miller MD, Margot N, Lu B, et al. Genotypic and pheno-typic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004;189(5):837–846.
- Molina JM, Marcelin AG, Pavie J, et al. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial. J Infect Dis. 2005;191(6):840–847.
- Castagna A, Danise A, Menzo S, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS. 2006;20(6):795–803.
- Sproat M, Pozniak AL, Peeters M, et al. The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine. Antivir Ther 2005;10(2):357–361.
- Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, Petro-poulos CJ. Broad nucleoside reverse-transcriptase inhibi-tor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis. 2003;188(7):992–1000.
- Bartlett JA, Fath MJ, Demasi R, et al. An updated system-atic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS. 2006;20(16):2051–2064.
- Harries AD, Zachariah R, van Oosterhout JJ, et al. Diag-nosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives. Lancet Infect Dis. 2010;10(1):60–65.
- Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med. 2006;14(3):125–130.
- DeJesus E, Herrera G, Teofilo E, et al. Abacavir versus zid-ovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis. 2004;39(7):1038–1046.
- Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz ver-sus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr 2006 ;43(5):535–540 .
- French M, Amin J, Roth N, et al. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucle-oside analogues and nevirapine for previously untreated HIV-1 infection: the OzCombo 2 study. HIV Clin Trials. 2002 ;3(3): 177–185.
- Carr A, Chuah J, Hudson J, et al. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indina-vir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS. 2000;14(9):1171–1180.
- Humphreys E, Hernandez LB, Rutherford G. Antiretroviral regimes for patients with HIV who fail first-line antiretroviral therapy. Cochrane Database Syst Rev. 2007; (4):CD006517. doi: 10.1002/14651858.CD14006517.pub14651852.